Donald James Annino, Jr., D.M.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 27 | 2024 | 2930 | 1.720 |
Why?
|
| Neck Dissection | 7 | 2011 | 201 | 1.020 |
Why?
|
| Facial Transplantation | 5 | 2021 | 220 | 1.000 |
Why?
|
| Carcinoma, Squamous Cell | 18 | 2024 | 4049 | 0.890 |
Why?
|
| Osteoradionecrosis | 1 | 2022 | 51 | 0.810 |
Why?
|
| Free Tissue Flaps | 2 | 2024 | 335 | 0.760 |
Why?
|
| Esophageal Stenosis | 4 | 2013 | 196 | 0.610 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2022 | 798 | 0.590 |
Why?
|
| Paranasal Sinuses | 1 | 2020 | 267 | 0.580 |
Why?
|
| Endoscopy | 4 | 2020 | 1854 | 0.570 |
Why?
|
| Enophthalmos | 2 | 2008 | 34 | 0.550 |
Why?
|
| Maxillary Sinusitis | 2 | 2008 | 40 | 0.540 |
Why?
|
| Rhinoplasty | 1 | 2020 | 241 | 0.540 |
Why?
|
| Maxillary Sinus | 2 | 2008 | 172 | 0.490 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2022 | 996 | 0.480 |
Why?
|
| Orbital Diseases | 2 | 2008 | 178 | 0.470 |
Why?
|
| Dilatation | 3 | 2013 | 311 | 0.450 |
Why?
|
| Neoplasms, Unknown Primary | 3 | 2022 | 102 | 0.410 |
Why?
|
| Mouth Neoplasms | 4 | 2024 | 597 | 0.390 |
Why?
|
| Deglutition Disorders | 4 | 2011 | 640 | 0.340 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2020 | 306 | 0.310 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2008 | 121 | 0.280 |
Why?
|
| Radiation Injuries | 2 | 2019 | 1196 | 0.270 |
Why?
|
| Relative Biological Effectiveness | 1 | 2008 | 313 | 0.270 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2022 | 492 | 0.250 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 548 | 0.240 |
Why?
|
| Facial Neuralgia | 1 | 2003 | 10 | 0.230 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2005 | 137 | 0.230 |
Why?
|
| Laryngectomy | 2 | 2003 | 245 | 0.220 |
Why?
|
| Toothache | 1 | 2003 | 31 | 0.220 |
Why?
|
| Lipectomy | 1 | 2005 | 114 | 0.220 |
Why?
|
| Pharyngectomy | 1 | 2003 | 45 | 0.220 |
Why?
|
| Larynx | 1 | 2008 | 492 | 0.220 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 109 | 0.220 |
Why?
|
| Facial Injuries | 3 | 2014 | 190 | 0.210 |
Why?
|
| Ultrasonic Therapy | 1 | 2005 | 216 | 0.210 |
Why?
|
| HIV Protease Inhibitors | 1 | 2005 | 430 | 0.210 |
Why?
|
| Mitomycin | 1 | 2003 | 261 | 0.210 |
Why?
|
| Pharyngeal Diseases | 1 | 2003 | 134 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2011 | 1788 | 0.190 |
Why?
|
| Face | 2 | 2020 | 1029 | 0.190 |
Why?
|
| Nasolacrimal Duct | 1 | 2022 | 79 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2024 | 9410 | 0.180 |
Why?
|
| Middle Aged | 41 | 2024 | 223233 | 0.180 |
Why?
|
| Combined Modality Therapy | 13 | 2013 | 8535 | 0.170 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 1639 | 0.170 |
Why?
|
| Graft Rejection | 4 | 2021 | 4498 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 2902 | 0.170 |
Why?
|
| Nasal Mucosa | 2 | 2020 | 416 | 0.170 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 280 | 0.160 |
Why?
|
| Retrospective Studies | 23 | 2024 | 81659 | 0.160 |
Why?
|
| Male | 49 | 2024 | 364203 | 0.150 |
Why?
|
| Radiotherapy Dosage | 6 | 2022 | 2915 | 0.150 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 435 | 0.150 |
Why?
|
| Microsurgery | 1 | 2003 | 798 | 0.150 |
Why?
|
| Triage | 1 | 2024 | 995 | 0.140 |
Why?
|
| Esophagoscopy | 2 | 2013 | 398 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2011 | 3552 | 0.140 |
Why?
|
| Postoperative Complications | 5 | 2021 | 15824 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2014 | 20741 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 980 | 0.140 |
Why?
|
| Aged | 32 | 2024 | 171319 | 0.130 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 4838 | 0.130 |
Why?
|
| Qualitative Research | 2 | 2024 | 3139 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 11872 | 0.130 |
Why?
|
| Female | 41 | 2024 | 396660 | 0.130 |
Why?
|
| Surgical Flaps | 2 | 2003 | 1680 | 0.120 |
Why?
|
| Adult | 28 | 2024 | 223317 | 0.120 |
Why?
|
| Humans | 59 | 2024 | 767040 | 0.120 |
Why?
|
| Treatment Outcome | 17 | 2021 | 65295 | 0.120 |
Why?
|
| Ear, External | 1 | 1995 | 165 | 0.120 |
Why?
|
| Zenker Diverticulum | 1 | 2014 | 28 | 0.110 |
Why?
|
| Epistaxis | 1 | 2014 | 117 | 0.110 |
Why?
|
| Surgical Stapling | 1 | 2014 | 98 | 0.110 |
Why?
|
| Sphenoid Bone | 1 | 2014 | 176 | 0.110 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2013 | 23 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2005 | 3468 | 0.110 |
Why?
|
| Reoperation | 2 | 2021 | 4325 | 0.110 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2007 | 243 | 0.110 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 59548 | 0.100 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 904 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2024 | 3618 | 0.090 |
Why?
|
| Laryngeal Neoplasms | 3 | 2011 | 514 | 0.090 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 223 | 0.090 |
Why?
|
| Syndrome | 2 | 2008 | 3271 | 0.090 |
Why?
|
| Neck | 2 | 2005 | 736 | 0.090 |
Why?
|
| Vincristine | 1 | 1992 | 1040 | 0.090 |
Why?
|
| Deglutition | 1 | 2011 | 208 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 3232 | 0.080 |
Why?
|
| Airway Obstruction | 1 | 2014 | 672 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2019 | 24299 | 0.080 |
Why?
|
| Vocal Cord Paralysis | 1 | 1992 | 275 | 0.080 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2009 | 95 | 0.080 |
Why?
|
| Recovery of Function | 3 | 2014 | 2978 | 0.080 |
Why?
|
| Pleural Neoplasms | 1 | 2013 | 584 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1761 | 0.070 |
Why?
|
| Lymphatic Metastasis | 3 | 2010 | 2900 | 0.070 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 11217 | 0.070 |
Why?
|
| Cancer Care Facilities | 3 | 2019 | 427 | 0.070 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2006 | 26 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 876 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 13650 | 0.070 |
Why?
|
| Models, Economic | 1 | 2009 | 719 | 0.060 |
Why?
|
| Hospitalization | 2 | 2020 | 10815 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 391 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2008 | 364 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 6844 | 0.060 |
Why?
|
| Survival Analysis | 5 | 2019 | 10092 | 0.060 |
Why?
|
| Diplopia | 1 | 2005 | 217 | 0.060 |
Why?
|
| Leukoplakia, Oral | 1 | 2024 | 79 | 0.050 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2003 | 113 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 2075 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2008 | 1966 | 0.050 |
Why?
|
| Eating | 1 | 2010 | 1541 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 1061 | 0.050 |
Why?
|
| Frontal Sinus | 1 | 2002 | 51 | 0.050 |
Why?
|
| Orbit | 1 | 2005 | 459 | 0.050 |
Why?
|
| Dermoid Cyst | 1 | 2002 | 92 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2003 | 703 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2024 | 41718 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 12536 | 0.050 |
Why?
|
| Parotid Gland | 1 | 2022 | 178 | 0.050 |
Why?
|
| Survival Rate | 3 | 2010 | 12823 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2010 | 6331 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3944 | 0.040 |
Why?
|
| Nose Neoplasms | 1 | 2002 | 250 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2003 | 1104 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2022 | 367 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2005 | 9362 | 0.040 |
Why?
|
| Prognosis | 4 | 2024 | 29963 | 0.040 |
Why?
|
| Skull Base Neoplasms | 1 | 2002 | 279 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2005 | 1597 | 0.040 |
Why?
|
| Patient Selection | 1 | 2010 | 4256 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2022 | 1965 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 11097 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 4648 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2009 | 896 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2024 | 2741 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 4282 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 52 | 0.030 |
Why?
|
| Quality of Life | 4 | 2024 | 13485 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2022 | 1139 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2019 | 659 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2024 | 6067 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2021 | 1271 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 420 | 0.030 |
Why?
|
| Ear Canal | 1 | 1995 | 149 | 0.030 |
Why?
|
| Length of Stay | 2 | 2021 | 6489 | 0.030 |
Why?
|
| Laryngismus | 1 | 1994 | 28 | 0.030 |
Why?
|
| Vocal Cords | 2 | 2000 | 520 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 15424 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2016 | 453 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6513 | 0.030 |
Why?
|
| Thermosensing | 1 | 2013 | 56 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 6550 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 1677 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 1661 | 0.030 |
Why?
|
| Laryngeal Muscles | 1 | 1994 | 107 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 39317 | 0.030 |
Why?
|
| Acute Disease | 1 | 2003 | 7236 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 518 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 21178 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 705 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2021 | 8732 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2014 | 310 | 0.020 |
Why?
|
| Botulinum Toxins | 1 | 1994 | 191 | 0.020 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2005 | 1897 | 0.020 |
Why?
|
| Aneurysm, False | 1 | 2014 | 263 | 0.020 |
Why?
|
| Respiratory Sounds | 2 | 1994 | 702 | 0.020 |
Why?
|
| Hemostasis | 1 | 2014 | 467 | 0.020 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 52 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 1412 | 0.020 |
Why?
|
| Touch | 1 | 2013 | 313 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 655 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 15925 | 0.020 |
Why?
|
| Xerostomia | 1 | 2010 | 94 | 0.020 |
Why?
|
| Voice Disorders | 1 | 1994 | 286 | 0.020 |
Why?
|
| Health Personnel | 1 | 2023 | 3387 | 0.020 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2013 | 354 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2599 | 0.020 |
Why?
|
| Melanoma | 1 | 2007 | 5702 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 2209 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 5519 | 0.020 |
Why?
|
| DNA | 1 | 2022 | 7210 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 598 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2014 | 1263 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2011 | 325 | 0.020 |
Why?
|
| Surgical Wound Infection | 2 | 2011 | 1547 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2013 | 1836 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2021 | 3467 | 0.020 |
Why?
|
| Boston | 2 | 2011 | 9360 | 0.020 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2007 | 59 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 4745 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2007 | 101 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 10748 | 0.020 |
Why?
|
| Respiration | 1 | 1994 | 1655 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 1992 | 714 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 575 | 0.020 |
Why?
|
| Carboplatin | 1 | 2009 | 790 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1405 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 665 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 976 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 6360 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 74886 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 461 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 2952 | 0.020 |
Why?
|
| Young Adult | 3 | 2017 | 59980 | 0.010 |
Why?
|
| Base Sequence | 1 | 2016 | 12414 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 1403 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 633 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2009 | 1652 | 0.010 |
Why?
|
| Adenoma | 1 | 2014 | 2155 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3599 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2019 | 3854 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3667 | 0.010 |
Why?
|
| Cisplatin | 1 | 2009 | 1656 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 1741 | 0.010 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2002 | 16 | 0.010 |
Why?
|
| Diet | 2 | 2014 | 8089 | 0.010 |
Why?
|
| Cranial Nerve Injuries | 1 | 2002 | 27 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 9245 | 0.010 |
Why?
|
| Incidence | 2 | 2014 | 21526 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2008 | 903 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2009 | 1728 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8628 | 0.010 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2002 | 87 | 0.010 |
Why?
|
| Recurrence | 1 | 2014 | 8504 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 26325 | 0.010 |
Why?
|
| Adolescent | 2 | 2023 | 89046 | 0.010 |
Why?
|
| Travel | 1 | 2006 | 805 | 0.010 |
Why?
|
| Meningitis | 1 | 2002 | 219 | 0.010 |
Why?
|
| Age of Onset | 1 | 2007 | 3344 | 0.010 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 2215 | 0.010 |
Why?
|
| Dura Mater | 1 | 2002 | 292 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2020 | 54886 | 0.010 |
Why?
|
| Thyroid Cartilage | 1 | 2000 | 46 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 9532 | 0.010 |
Why?
|
| Surgical Mesh | 1 | 2002 | 315 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2009 | 2697 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2014 | 4854 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 9612 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 4968 | 0.010 |
Why?
|
| Craniotomy | 1 | 2002 | 736 | 0.010 |
Why?
|
| Bone Transplantation | 1 | 2002 | 921 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2006 | 2116 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 5537 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2009 | 6260 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 2002 | 1275 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 7587 | 0.010 |
Why?
|
| Hypertension | 1 | 2014 | 8615 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 14672 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 11063 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 9108 | 0.010 |
Why?
|
| Laser Therapy | 1 | 2000 | 1108 | 0.010 |
Why?
|
| Disease Progression | 1 | 2009 | 13646 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 36582 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 6975 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 8940 | 0.010 |
Why?
|
| Infant | 1 | 1992 | 36485 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1992 | 42606 | 0.010 |
Why?
|
| Time Factors | 1 | 1994 | 40154 | 0.000 |
Why?
|